v3.25.3
Debt, Cash and Cash Equivalents - Summary of Changes in Financial Position (Details) - EUR (€)
€ in Millions
Jun. 30, 2025
Dec. 31, 2024
Jun. 30, 2024
 [2]
Dec. 31, 2023
 [2]
Cash and cash equivalents [abstract]        
Long-term debt [1] € 13,200 € 11,791    
Short-term debt and current portion of long-term debt [1] 7,309 4,209    
Interest rate and currency derivatives used to manage debt 10 137    
Total debt 20,519 16,137    
Cash and cash equivalents [1] (15,359) (7,441) € (6,795) € (8,710)
Interest rate and currency derivatives used to manage cash and cash equivalents (58) 76    
Net debt [3] 5,102 8,772    
Lease liabilities € 1,776 € 1,906    
[1] These unaudited condensed half year consolidated financial statements as of June 30, 2025 should be read in conjunction with Sanofi’s audited consolidated financial statements as of December 31, 2024.
[2] Figures for the 2024 comparative period have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[3] Net debt does not include lease liabilities, which amounted to €1,776 million as of June 30, 2025 and €1,906 million as of December 31, 2024.